Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Cholangiocarcinoma | Research

Tumor burden score and carcinoembryonic antigen predict outcomes in patients with intrahepatic cholangiocarcinoma following liver resection: a multi‑institutional analysis

Authors: Jun Fu, Lifang Zheng, Shicuan Tang, Kongying Lin, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Kui Wang, Haitao Li, Yongyi Zeng

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

The prognostic significance of tumor burden score (TBS) in relation to carcinoembryonic antigen (CEA) has not been investigated among patients undergoing hepatectomy for intrahepatic cholangiocarcinoma (ICC). This study aimed to develop and validate a simplified model, a combination of TBS and CEA (CTC grade), for predicting the long-term outcomes of postoperative ICC patients.

Methods

Patients who underwent curative − intent resection of ICC between 2011 and 2019 were identified from a large multi − institutional database. The impact of TBS, CEA, and the CTC grade on overall survival (OS) and recurrence − free survival (RFS) was evaluated in both the derivation and validation cohorts. The receiver operating characteristic curve was utilized for assessing the predictive accuracy of the model. Subgroup analyses were performed across 8th TNM stage system stratified by CTC grade to assess the discriminatory capacity within the same TNM stage.

Results

A total of 812 patients were included in the derivation cohort and 266 patients in the validation cohort. Survival varied based on CEA (low: 36.7% vs. high: 9.0%) and TBS (low: 40.3% vs. high: 17.6%) in relation to 5 − year survival (both p < 0.001). As expected, patients with low CTC grade (i.e., low TBS/low CEA) were associated with the best OS as well as RFS, while high CTC grade (i.e., high TBS/high CEA) correlated to the worst outcomes. The model exhibited well performance in both the derivation cohort (area under the curve of 0.694) and the validation cohort (0.664). The predictive efficacy of the CTC grade system remains consistently stable across TNM stages I and III/IV.

Conclusion

The CTC grade, a composite parameter derived from the combination of TBS and CEA levels, served as an easy − to − use tool and performed well in stratifying patients with ICC relative to OS and RFS.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Siegel RL, Miller KD, Jemal A, Cancer statistics. 2020. CA Cancer J Clin. 2020;70(1):7–30. Siegel RL, Miller KD, Jemal A, Cancer statistics. 2020. CA Cancer J Clin. 2020;70(1):7–30.
3.
go back to reference Gravely AK, Vibert E, Sapisochin G. Surgical treatment of intrahepatic cholangiocarcinoma. J Hepatol. 2022;77(3):865–7.CrossRefPubMed Gravely AK, Vibert E, Sapisochin G. Surgical treatment of intrahepatic cholangiocarcinoma. J Hepatol. 2022;77(3):865–7.CrossRefPubMed
4.
go back to reference Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198–222.CrossRefPubMed Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198–222.CrossRefPubMed
5.
go back to reference Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848–56.CrossRefPubMed Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848–56.CrossRefPubMed
6.
go back to reference Alaimo L, Moazzam Z, Endo Y, et al. Long-term recurrence-free and overall survival Differ Based on Common, proliferative, and inflammatory subtypes after resection of Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023;30(3):1392–403.CrossRefPubMed Alaimo L, Moazzam Z, Endo Y, et al. Long-term recurrence-free and overall survival Differ Based on Common, proliferative, and inflammatory subtypes after resection of Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023;30(3):1392–403.CrossRefPubMed
7.
go back to reference Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109–21.CrossRefPubMed Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109–21.CrossRefPubMed
8.
go back to reference Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRefPubMed Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRefPubMed
9.
go back to reference Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an eastern and western experience. JAMA Surg. 2014;149(5):432–8.CrossRefPubMed Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an eastern and western experience. JAMA Surg. 2014;149(5):432–8.CrossRefPubMed
10.
go back to reference Merath K, Chen Q, Bagante F, et al. A multi-institutional International Analysis of Textbook outcomes among patients undergoing curative-intent resection of Intrahepatic Cholangiocarcinoma. JAMA Surg. 2019;154(6):e190571.CrossRefPubMedPubMedCentral Merath K, Chen Q, Bagante F, et al. A multi-institutional International Analysis of Textbook outcomes among patients undergoing curative-intent resection of Intrahepatic Cholangiocarcinoma. JAMA Surg. 2019;154(6):e190571.CrossRefPubMedPubMedCentral
11.
go back to reference Uenishi T, Ariizumi S, Aoki T, et al. Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese society of Hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci. 2014;21(7):499–508.CrossRefPubMed Uenishi T, Ariizumi S, Aoki T, et al. Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese society of Hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci. 2014;21(7):499–508.CrossRefPubMed
12.
go back to reference Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.CrossRefPubMed Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.CrossRefPubMed
13.
go back to reference Park SY, Nomogram. An analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.CrossRefPubMed Park SY, Nomogram. An analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.CrossRefPubMed
14.
go back to reference Rhee H, Choi SH, Park JH, et al. Preoperative magnetic resonance imaging-based prognostic model for mass-forming intrahepatic cholangiocarcinoma. Liver Int. 2022;42(4):930–41.CrossRefPubMed Rhee H, Choi SH, Park JH, et al. Preoperative magnetic resonance imaging-based prognostic model for mass-forming intrahepatic cholangiocarcinoma. Liver Int. 2022;42(4):930–41.CrossRefPubMed
15.
go back to reference Sasaki K, Morioka D, Conci S, et al. The Tumor Burden score: a New Metro-ticket Prognostic Tool for Colorectal Liver metastases based on Tumor size and number of tumors. Ann Surg. 2018;267(1):132–41.CrossRefPubMed Sasaki K, Morioka D, Conci S, et al. The Tumor Burden score: a New Metro-ticket Prognostic Tool for Colorectal Liver metastases based on Tumor size and number of tumors. Ann Surg. 2018;267(1):132–41.CrossRefPubMed
16.
go back to reference Addeo P, Jedidi I, Locicero A, et al. Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2019;23(9):1801–9.CrossRefPubMed Addeo P, Jedidi I, Locicero A, et al. Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2019;23(9):1801–9.CrossRefPubMed
17.
go back to reference Chen Y, Weng S. Reappraisal of the T category for Solitary Intrahepatic Cholangiocarcinoma by Tumor size in 611 early-stage (T1-2N0M0) patients after Hepatectomy: a Surveillance, Epidemiology, and end results (SEER) analysis. J Gastrointest Surg. 2021;25(8):1989–99.CrossRefPubMed Chen Y, Weng S. Reappraisal of the T category for Solitary Intrahepatic Cholangiocarcinoma by Tumor size in 611 early-stage (T1-2N0M0) patients after Hepatectomy: a Surveillance, Epidemiology, and end results (SEER) analysis. J Gastrointest Surg. 2021;25(8):1989–99.CrossRefPubMed
18.
go back to reference Zeng L, He C, Li X. Prognosis for intrahepatic cholangiocarcinoma after liver transplantation by size of tumor. Surgery. 2023;174(4):1094.CrossRefPubMed Zeng L, He C, Li X. Prognosis for intrahepatic cholangiocarcinoma after liver transplantation by size of tumor. Surgery. 2023;174(4):1094.CrossRefPubMed
19.
go back to reference Tsilimigras DI, Moris D, Hyer JM, et al. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg. 2020;107(7):854–64.CrossRefPubMed Tsilimigras DI, Moris D, Hyer JM, et al. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg. 2020;107(7):854–64.CrossRefPubMed
20.
go back to reference Vitale A, Lai Q, Farinati F, et al. Utility of Tumor Burden score to stratify prognosis of patients with Hepatocellular Cancer: results of 4759 cases from ITA.LI.CA Study Group. J Gastrointest Surg. 2018;22(5):859–71.CrossRefPubMed Vitale A, Lai Q, Farinati F, et al. Utility of Tumor Burden score to stratify prognosis of patients with Hepatocellular Cancer: results of 4759 cases from ITA.LI.CA Study Group. J Gastrointest Surg. 2018;22(5):859–71.CrossRefPubMed
21.
go back to reference Endo Y, Sasaki K, Moazzam Z, et al. Higher Tumor Burden Status dictates the impact of Surgical Margin Status on overall survival in patients undergoing resection of Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023;30(4):2023–32.CrossRefPubMed Endo Y, Sasaki K, Moazzam Z, et al. Higher Tumor Burden Status dictates the impact of Surgical Margin Status on overall survival in patients undergoing resection of Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023;30(4):2023–32.CrossRefPubMed
22.
go back to reference Deng G, Ren JK, Wang HT, et al. Tumor burden score dictates prognosis of patients with combined hepatocellular cholangiocarcinoma undergoing hepatectomy. Front Oncol. 2022;12:977111.CrossRefPubMed Deng G, Ren JK, Wang HT, et al. Tumor burden score dictates prognosis of patients with combined hepatocellular cholangiocarcinoma undergoing hepatectomy. Front Oncol. 2022;12:977111.CrossRefPubMed
23.
go back to reference Endo Y, Lima HA, Alaimo L, et al. Preoperative risk score (PreopScore) to predict overall survival after resection for hepatocellular carcinoma. HPB (Oxford). 2023;25(3):353–62.CrossRefPubMed Endo Y, Lima HA, Alaimo L, et al. Preoperative risk score (PreopScore) to predict overall survival after resection for hepatocellular carcinoma. HPB (Oxford). 2023;25(3):353–62.CrossRefPubMed
24.
go back to reference Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of Multinodular Hepatocellular Carcinoma beyond the Milan Criteria. Ann Surg. 2020;272(4):574–81.CrossRefPubMed Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of Multinodular Hepatocellular Carcinoma beyond the Milan Criteria. Ann Surg. 2020;272(4):574–81.CrossRefPubMed
25.
go back to reference Ding HF, Yang T, Lv Y, Zhang XF, Pawlik TM. Development and validation of an α-Fetoprotein tumor burden score model to Predict Postrecurrence Survival among patients with Hepatocellular Carcinoma. J Am Coll Surg. 2023;236(5):982–92.CrossRefPubMed Ding HF, Yang T, Lv Y, Zhang XF, Pawlik TM. Development and validation of an α-Fetoprotein tumor burden score model to Predict Postrecurrence Survival among patients with Hepatocellular Carcinoma. J Am Coll Surg. 2023;236(5):982–92.CrossRefPubMed
26.
go back to reference Li H, Liu R, Qiu H, et al. Tumor burden score stratifies prognosis of patients with Intrahepatic Cholangiocarcinoma after hepatic resection: a Retrospective, multi-institutional study. Front Oncol. 2022;12:829407.CrossRefPubMedPubMedCentral Li H, Liu R, Qiu H, et al. Tumor burden score stratifies prognosis of patients with Intrahepatic Cholangiocarcinoma after hepatic resection: a Retrospective, multi-institutional study. Front Oncol. 2022;12:829407.CrossRefPubMedPubMedCentral
27.
go back to reference Munir MM, Endo Y, Lima HA, et al. Albumin-bilirubin Grade and Tumor Burden score predict outcomes among patients with Intrahepatic Cholangiocarcinoma after hepatic resection: a multi-institutional analysis. J Gastrointest Surg. 2023;27(3):544–54.CrossRefPubMed Munir MM, Endo Y, Lima HA, et al. Albumin-bilirubin Grade and Tumor Burden score predict outcomes among patients with Intrahepatic Cholangiocarcinoma after hepatic resection: a multi-institutional analysis. J Gastrointest Surg. 2023;27(3):544–54.CrossRefPubMed
28.
go back to reference Jaklitsch M, Petrowsky H. The power to predict with biomarkers: carbohydrate antigen 19– 9 (CA 19– 9) and carcinoembryonic antigen (CEA) serum markers in intrahepatic cholangiocarcinoma. Transl Gastroenterol Hepatol. 2019;4:23.CrossRefPubMedPubMedCentral Jaklitsch M, Petrowsky H. The power to predict with biomarkers: carbohydrate antigen 19– 9 (CA 19– 9) and carcinoembryonic antigen (CEA) serum markers in intrahepatic cholangiocarcinoma. Transl Gastroenterol Hepatol. 2019;4:23.CrossRefPubMedPubMedCentral
29.
go back to reference Qiang Z, Zhang W, Jin S, et al. Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: a retrospective cohort study. Ann Hepatol. 2021;20:100242.CrossRefPubMed Qiang Z, Zhang W, Jin S, et al. Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: a retrospective cohort study. Ann Hepatol. 2021;20:100242.CrossRefPubMed
30.
go back to reference Moazzam Z, Alaimo L, Endo Y, et al. Combined Tumor Burden score and Carbohydrate Antigen 19– 9 Grading System to Predict outcomes among patients with Intrahepatic Cholangiocarcinoma. J Am Coll Surg. 2023;236(4):804–13.CrossRefPubMed Moazzam Z, Alaimo L, Endo Y, et al. Combined Tumor Burden score and Carbohydrate Antigen 19– 9 Grading System to Predict outcomes among patients with Intrahepatic Cholangiocarcinoma. J Am Coll Surg. 2023;236(4):804–13.CrossRefPubMed
31.
go back to reference Fu J, Chen Q, Yu Y, et al. Impact of portal hypertension on short- and long-term outcomes after liver resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. Cancer Med. 2021;10(20):6985–97.CrossRefPubMedPubMedCentral Fu J, Chen Q, Yu Y, et al. Impact of portal hypertension on short- and long-term outcomes after liver resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. Cancer Med. 2021;10(20):6985–97.CrossRefPubMedPubMedCentral
32.
go back to reference Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351–5.CrossRefPubMed Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351–5.CrossRefPubMed
33.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral
34.
go back to reference Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34(4):219–28.CrossRefPubMedPubMedCentral Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34(4):219–28.CrossRefPubMedPubMedCentral
35.
go back to reference Tian M, Liu W, Tao C, et al. Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS(ICC) -applied prediction model. Cancer Sci. 2020;111(4):1084–92.CrossRefPubMedPubMedCentral Tian M, Liu W, Tao C, et al. Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS(ICC) -applied prediction model. Cancer Sci. 2020;111(4):1084–92.CrossRefPubMedPubMedCentral
36.
go back to reference Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.CrossRefPubMed Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.CrossRefPubMed
37.
go back to reference Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer. 2011;117(10):2170–7.CrossRefPubMed Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer. 2011;117(10):2170–7.CrossRefPubMed
38.
go back to reference Mason MC, et al. Time to rethink upfront surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant experience. Ann Surg Oncol. 2021;28:6725–35.CrossRefPubMed Mason MC, et al. Time to rethink upfront surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant experience. Ann Surg Oncol. 2021;28:6725–35.CrossRefPubMed
39.
go back to reference Khan SA, Tavolari S, Brandi G, Cholangiocarcinoma. Epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31.CrossRefPubMed Khan SA, Tavolari S, Brandi G, Cholangiocarcinoma. Epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31.CrossRefPubMed
40.
go back to reference Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic Cholangiocarcinoma: Continuing challenges and translational advances. Hepatology. 2019;69(4):1803–15.CrossRefPubMed Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic Cholangiocarcinoma: Continuing challenges and translational advances. Hepatology. 2019;69(4):1803–15.CrossRefPubMed
Metadata
Title
Tumor burden score and carcinoembryonic antigen predict outcomes in patients with intrahepatic cholangiocarcinoma following liver resection: a multi‑institutional analysis
Authors
Jun Fu
Lifang Zheng
Shicuan Tang
Kongying Lin
Shuguo Zheng
Xinyu Bi
Jianming Wang
Wei Guo
Fuyu Li
Jian Wang
Kui Wang
Haitao Li
Yongyi Zeng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12091-2

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine